Carzinophilin in advanced solid cancer
نویسندگان
چکیده
منابع مشابه
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
BACKGROUND With its potent inhibitory effects against Raf-1 kinase and vascular endothelial growth factor receptor-2, sorafenib is a novel oral anticancer agent targeting signal transduction and angiogenic pathways. This study is designed to combine sorafenib and gemcitabine due to their compatibility in preclinical models and nonoverlapping clinical toxicities. EXPERIMENTAL DESIGN An initial...
متن کاملEFFECTIVENESS OF CHEMOTHERAPY IN 54 CASES OF ADVANCED GASTRIC CANCER IN ISFAHAN
To determine the effectiveness of chemotherapy in the treatment of gastric cancer, a sample of 54 patients suffering from advanced adenocarcinomas were studied. The results of the study showed that the disease is more prevalent in the age group of56-60 years. The three major signs of this kind of cancer were almost equally present among both sexes in our patients. After chemotherapy, 74% o...
متن کاملSynthetic studies of carzinophilin. Part 1: Synthesis of 2-methylidene-1-azabicyclo[3.1.0]hexane systems related to carzinophilin
Synthesis of the model compounds of carzinophilin carrying 2-methylidene-1-aza-bicyclo[3.1.0]hexane systems was achieved. Formation of malonylidenes or N-acyl-glycinylidenepyrrolidines was carried out by utilizing Eschenmoser’s sulfide contraction or Herdeis’s condensation between the 2-methylthio-D-pyrrolone derivatives and ethyl nitroacetate, respectively. The 1-azabicyclo-[3.1.0]hexane syste...
متن کاملCancer Therapy: Clinical A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
Purpose: Bevacizumab is an antibody against vascular endothelial growth factor; sunitinib is an inhibitor of vascular endothelial growth factor and related receptors. The safety and maximum tolerated dose of sunitinib plus bevacizumab was assessed in this phase I trial. Experimental Design: Patients with advanced solid tumors were treated on a 3+3 trial design. Patients received sunitinib daily...
متن کاملCompanion Diagnostics & Cancer Biomarkers HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors
The objective of this study was to evaluate circulating hepatocyte growth factor (cHGF) as a pharmacodynamic biomarker of Met inhibition for onartuzumab (MetMAb, OA5D5v2) in a phase I trial in patients with advanced cancers and a phase II trial in non–small cell lung cancer (NSCLC). The phase I study was a dose escalation trial with onartuzumab administered i.v. once every three weeks. The phas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1960
ISSN: 0008-543X,1097-0142
DOI: 10.1002/1097-0142(196005/06)13:3<439::aid-cncr2820130303>3.0.co;2-4